| Li, Hong |
REPOSE-2, NCT05728775: REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry |
|
|
| Recruiting | 4 | 7188 | RoW | Remimazolam, Propofol | Nanfang Hospital of Southern Medical University | Anesthesia, Surgery-Complications | 12/24 | 12/27 | | |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
| Recruiting | N/A | 1250 | RoW | EEG(Electroencephalogram) change | Air Force Military Medical University, China | Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities | 03/23 | 04/23 | | |
NCT06308627: A One-year Trajectory of Depression Status Changes in Older Adults With MCI and SD: a Longitudinal Cohort Study |
|
|
| Completed | N/A | 466 | RoW | | Fujian Medical University | Mild Cognitive Impairment, Subthreshold Depression, Older Adults | 08/24 | 08/24 | | |
NCT05521295: Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome |
|
|
| Recruiting | N/A | 3600 | RoW | no intervention | Shengjing Hospital, Beijing Institutes of Life Science, Chinese Academy of Sciences | Infertility, Microbiome | 09/23 | 09/24 | | |
REMAIN-2, NCT05962125: The Role of Periodic Alveolar Recruitment Maneuvers in Intraoperative Protective Ventilation |
|
|
| Completed | N/A | 75 | RoW | periodic alveolar recruitment maneuvers, positive end-expiratory pressure | Sixth Affiliated Hospital, Sun Yat-sen University | Mechanical Power, Alveolar Recruitment Maneuvers, Protective Ventilation, Postoperative Pulmonary Complications | 11/23 | 12/23 | | |
NCT05442125: First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization |
|
|
| Recruiting | N/A | 1146 | RoW | Using DNA methylome to select embryos, Using morphologic score to select embryos | Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand | Reproductive Techniques, Assisted, DNA Methylation | 06/24 | 05/25 | | |
NDURE2, NCT04030130: Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC |
|
|
| Completed | N/A | 176 | US | NDURE | Medical University of South Carolina, National Cancer Institute (NCI) | Squamous Cell Carcinoma of Head and Neck | 12/23 | 01/24 | | |
NCT06706739: A Trial of Combined Subthreshold Depression in Older Adults With Mild Cognitive Impairment Participating in Art Games |
|
|
| Recruiting | N/A | 80 | RoW | Online art game intervention group | Fujian Medical University | Mild Cognitive Impairment, Subthreshold Depression | 12/24 | 12/24 | | |
| Completed | N/A | 1060 | RoW | periodic lung recruitment maneuvers | Sixth Affiliated Hospital, Sun Yat-sen University | Postoperative Complications, Abdominal Surgery, Intraoperative Mechanical Ventilation | 09/24 | 11/24 | | |
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer |
|
|
| Recruiting | N/A | 5000 | RoW | pepsinogen | Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital | Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection | 12/22 | 12/23 | | |
| Zhang, Cheng |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT06157060: Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA |
|
|
| Recruiting | N/A | 255 | RoW | circulating tumor DNA | Zhujiang Hospital | Hepatocellular Carcinoma Resectable | 11/23 | 12/26 | | |
NCT05813392: Digital Cognitive Behavioral Therapy for Insomnia for Chronic Insomnia in Breast Cancer Survivors |
|
|
| Recruiting | N/A | 264 | RoW | Digital Cognitive Behavioral Therapy for Insomnia | Peking University First Hospital, Shenzhen Zeen Health Technology Co., Ltd. | Chronic Insomnia | 08/25 | 08/26 | | |
NCT06573372: Evaluating the Diagnostic Efficacy of Smartwatch and Smartphone for Sleep Apnea |
|
|
| Recruiting | N/A | 295 | RoW | | Peking University First Hospital, OPPO | Sleep Apnea, Obstructive | 03/25 | 07/26 | | |
CGOG-EV-1001, NCT04993378: Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy |
|
|
| Recruiting | N/A | 40 | RoW | EV-array | Shen Lin | Advanced Gastric Adenocarcinoma, Immunotherapy | 04/21 | 07/21 | | |
| Weng, Jianyu |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT06451861: Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML |
|
|
| Not yet recruiting | 2 | 240 | RoW | Chidamide, Venetoclax, azacitidine, Anthracyclines or anthraquinones, idarubicin, daunorubicin, mitoxantrone, cytarabine | Guangdong Provincial People's Hospital | Acute Myeloid Leukemia | 12/26 | 06/27 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
NCT06122831: A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF) |
|
|
| Recruiting | 1/2 | 92 | RoW | TQ05105 Tablets, TQB3617 Capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Myelofibrosis | 12/26 | 04/27 | | |
NCT05320809: Study of 3D189 in Patients With Hematologic Malignancies |
|
|
| Active, not recruiting | 1 | 15 | RoW | 3D189 | 3D Medicines | Acute Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Higher-risk Myelodysplastic Syndrome | 12/24 | 12/24 | | |
| Liu, Yao |
| Recruiting | 4 | 174 | RoW | PEG-rhG-CSF, RhG-CSF | Chongqing University Cancer Hospital, CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Lymphoma | 01/24 | 06/24 | | |
NCT05786989: Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 4 | 32 | RoW | selinexor, Selective Inhibitor of Nuclear, KPT-330 | Chongqing University Cancer Hospital | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 03/24 | 09/24 | | |
SHINE-HF, NCT05583773: SHengXIaN-QuYu DEcoction in the Treatment of Heart Failure with Reduced Ejection Fraction |
|
|
| Recruiting | 4 | 336 | RoW | ShengXian-QuYu Decoction, Placebo | China-Japan Friendship Hospital | Heart Failure with Reduced Ejection Fraction | 04/25 | 12/25 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | 3 | 640 | Europe, Canada, US | Low Energy SLT, Standard Energy SLT | West Virginia University, University of Pittsburgh | Glaucoma and Ocular Hypertension | 06/27 | 08/27 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT06106841: TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL) |
|
|
| Recruiting | 1/2 | 39 | RoW | 400mg of TQB3909 tablets, 600mg of TQB3909 tablets | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Mantle Cell Lymphoma | 12/24 | 12/24 | | |
ELEVATION, NCT05800977: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma |
|
|
| Recruiting | 1/2 | 112 | RoW | Prizloncabtagene autoleucel, C-CAR039 | Shanghai AbelZeta Ltd. | Relapsed/Refractory Large B-Cell Lymphoma | 10/25 | 12/27 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06060080: Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma |
|
|
| Recruiting | N/A | 7 | RoW | pegylated recombinant human granulocyte-colony stimulating factor, PEG-rhG-CSF | Yao Liu | Lymphoma, Multiple Myeloma | 12/23 | 04/24 | | |
NCT06257082: Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities |
|
|
| Not yet recruiting | N/A | 1526 | US | Online Survey | University of Wisconsin, Madison, National Eye Institute (NEI) | Diabetic Retinopathy | 03/26 | 03/26 | | |
NCT05401175: Hematopoietic Stem Cell-containing Autologous Blood Transfusion for Bone Marrow Protection in Patients With Cervical Cancer |
|
|
| Recruiting | N/A | 40 | RoW | Autologous blood transfusion with haematopoietic stem cells | Chongqing University Cancer Hospital | Cervical Cancer | 04/25 | 04/27 | | |
NCT05401162: Chemotherapy Supported by Autologous Hematopoietic Stem Cells |
|
|
| Recruiting | N/A | 40 | RoW | Autologous blood transfusion with haematopoietic stem cells | Chongqing University Cancer Hospital | Ovarian Cancer | 05/25 | 05/27 | | |
NCT05254535: I-TRUST: Implementation of Teleophthalmology in Rural Health Systems Study |
|
|
| Enrolling by invitation | N/A | 10 | US | I-SITE, Implementation for Sustained Impact in Teleophthalmology | University of Wisconsin, Madison, National Eye Institute (NEI) | Diabetic Retinopathy | 12/26 | 01/27 | | |
NCT05773495: Implementation of Teleophthalmology in Urban Health Systems Study |
|
|
| Enrolling by invitation | N/A | 2000 | US | I-SITE Intervention, Usual Care Teleophthalmology | University of Wisconsin, Madison, National Eye Institute (NEI) | Diabetic Retinopathy | 08/26 | 08/26 | | |
| Ma, Dan |
| Recruiting | N/A | 1114 | RoW | TaTME, Transanal TME, LpTME, Laparoscopic TME | Sun Yat-sen University, Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University | Rectal Neoplasms Malignant, Surgery | 07/26 | 07/26 | | |
NCT04564989: Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC |
|
|
| Recruiting | N/A | 220 | US | | UNC Lineberger Comprehensive Cancer Center, Mayo Clinic, National Institute of Dental and Craniofacial Research (NIDCR) | Oropharyngeal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Head and Neck Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma | 11/33 | 11/33 | | |
| Yang, Yanli |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT06051409: A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. |
|
|
| Recruiting | 3 | 350 | RoW | Olverembatinib, Imatinib | Ascentage Pharma Group Inc., HealthQuest Pharma Inc. | Ph+ ALL | 12/24 | 10/28 | | |
NCT05709093: A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS) |
|
|
| Recruiting | 3 | 552 | RoW | Lemzoparlimab+Azacitidine (AZA), Azacitidine (AZA) | TJ Biopharma Co., Ltd. | Myelodysplastic Syndromes(MDS) | 03/27 | 03/27 | | |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
NCT05607498: First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma |
|
|
| Recruiting | 1 | 150 | RoW | EMB07 | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma | 10/25 | 03/26 | | |
| Zi, Wenjie |
| Recruiting | 2/3 | 544 | RoW | rhTNK-tPA, TNKase, TNK-tPA, Endovascular treatment, intra-arterial treatment, interventional therapy | Xinqiao Hospital of Chongqing, CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD | Stroke, Acute, Stroke, Ischemic | 12/25 | 03/26 | | |
| Feng, Yimei |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
